載入中
NASDAQHealthcareDrug Manufacturers - General
最新資料
US$0.6664
−US$0.039 · -5.53%
MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog. This compound is undergoing investigation for its potential to address anxiety and the cognitive impairments frequently observed in adult patients suffering from early-stage dementia. The firm's lead candidate, MIRA1a, is a synthetic cannabinoid analog engineered to alleviate both anxiety and chronic pain through its interaction with cannabinoid type 1 and type 2 receptors. Originally established in 2020 as MIRA1a Therapeutics, Inc., MIRA Pharmaceuticals, Inc. maintains its headquarters in Baltimore, Maryland.
收盤時
US$0.6664
−US$0.039 · -5.53%
盤中時間採用ET。市場資料可能有所延遲。
MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog. This compound is undergoing investigation for its potential to address anxiety and the cognitive impairments frequently observed in adult patients suffering from early-stage dementia. The firm's lead candidate, MIRA1a, is a synthetic cannabinoid analog engineered to alleviate both anxiety and chronic pain through its interaction with cannabinoid type 1 and type 2 receptors. Originally established in 2020 as MIRA1a Therapeutics, Inc., MIRA Pharmaceuticals, Inc. maintains its headquarters in Baltimore, Maryland.
日內區間
目前US$0.6664
52週區間
目前US$0.6664
盤中時間採用ET。市場資料可能有所延遲。
MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog. This compound is undergoing investigation for its potential to address anxiety and the cognitive impairments frequently observed in adult patients suffering from early-stage dementia. The firm's lead candidate, MIRA1a, is a synthetic cannabinoid analog engineered to alleviate both anxiety and chronic pain through its interaction with cannabinoid type 1 and type 2 receptors. Originally established in 2020 as MIRA1a Therapeutics, Inc., MIRA Pharmaceuticals, Inc. maintains its headquarters in Baltimore, Maryland.
日內區間
目前US$0.6664
52週區間
目前US$0.6664
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 171.98萬 USD | 330.56萬 USD | 157.3萬 USD | 235.15萬 USD | 68.44萬 USD |
| 銷售、一般及管理費用 | 877.33萬 USD | 471.28萬 USD | 649.95萬 USD | 299.21萬 USD | 77.01萬 USD |
| 營業費用 | 1049.31萬 USD | 801.83萬 USD | 852.6萬 USD | 704.79萬 USD | 215.22萬 USD |
| 利息收入 | 9.89萬 USD | — | — | — | — |
| 利息支出 | — | 16.57萬 USD | 345.63萬 USD | 1.03萬 USD | 2.44萬 USD |
| 折舊和攤銷 | — | — | — | 704.79萬 USD | 215.22萬 USD |
| 營業利益 | −1049.31萬 USD | −801.83萬 USD | −852.6萬 USD | −704.79萬 USD | −215.22萬 USD |
| 淨利 | −1044.25萬 USD | −785.27萬 USD | −1198.23萬 USD | −705.82萬 USD | −217.65萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
